***“New Clinical Opportunities in Digital Health”***

***Special Edition, J. Commercial Biotechnology***

***Anticipated Publication Date (February 2022)***

***An Invitation to all who presented talks at the Symposium on New Clinical and Commercial Opportunities in Digital Health – a webinar organized and hosted by UC San Diego on October 27, 2021. You are invited to contribute a paper on your topic to be published as part of a Special Edition of the international Journal of Commercial Biotechnology.***

***Submissions from others who didn't present at the 10/27/21 Symposium will also be considered as long as they align with the purpose of this Supplement and follow the same editorial guidelines.***

***PLEASE SUBMIT YOUR INTENT TO PUBLISH BY DECEMBER 1, 2021; PAPERS TO BE SUBMITTED BY JANUARY 15, 2022. SEND BY EMAIL TO:***

***"Houston, Justina" <jhouston@ucsd.edu>, Andrew McCulloch <amcculloch@eng.ucsd.edu>, Kevin Patrick <kpatrick@ucsd.edu>, Arthur A Boni*** [***boni@andrew.cmu.edu***](mailto:boni@andrew.cmu.edu)***.***

***The organizers also request permission from all presenters to post their PPT presentations from the symposium to the UCSD conference website. That too is requested by Dec. 1, 2021.***

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

***ALL ACCEPTED PAPERS TO BE PUBLISHED IN J. COMMERCIAL BIOTECHNOLOGY AS FOLLOWS***

***“New Clinical Opportunities in Digital Health”***

***Special Edition, J. Commercial Biotechnology***

***Anticipated Publication Date (February 2022)***

***Special Edition Co-Editors, Andrew McCulloch, Ph.D., Kevin Patrick, MD, MS, and Arthur A. Boni, Ph. D***

***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_***

***Background, Rationale, and Paper Preparation Guidelines***

This Special Edition of the Journal of Commercial Biotechnology (JCB) is dedicated to the publication of papers by those who were invited to participate, and who presented papers at the **Symposium on New Clinical Opportunities in Digital Health** held on October 27, 2021. The day-long symposium attracted over 200 participants, and was held in a “Zoom Webinar format”. Sessions were organized as follows. A **Plenary Session** focused on **Healthcare and the Tech Industry**; three sessions on emerging opportunities (**Remote Monitoring and Mobile Health; Sensors, Wearables and POC; AI and Computational Medicine**). We also included a concluding session dedicated to **Commercialization** to highlight the importance of using “the best business practices and methodologies” for commercializing emerging, transformational technologies in Digital Health.

This symposium was organized and hosted by the following UC San Diego organizations: the Institute of Engineering in Medicine; the Center for Health Innovation at UC San Diego Health; the Institute for the Global Entrepreneur; and, by the Journal of Commercial Biotechnology.

## About the Journal of Commercial Biotechnology . <https://www.commercialbiotechnology.com/index.php/jcb>

The Journal of Commercial Biotechnology (JCB) is **published quarterly, and is** focused on leading thinking in the business of biotechnology management. It is the definitive international quarterly publication for life sciences business professionals**,** and has been in print since 1994**.** The Journal is designed specifically for those professionals who need to enhance their knowledge of business strategy and management, improve and advance their product development, and/or those who want to keep up-to-date with current industryissues and trends. The focus of JCB is on the life science industries, e.g. biopharma (biotechnology & pharmaceuticals, MedTech and Digital **H**ealth). A secondary focus is on food and agricultural  products and services to improve organisms.

Each issue published includes peer-reviewed, authoritative, cutting-edge articles and perspectives written by leading practitioners and researchers in the field.  We publish both submitted and solicited articles (including special editions), addressing topics such as:

* Management, Leadership, and collaborative teams
* Commercialization, Marketing, and Innovation strategies and best practices
* Entrepreneurship, including education
* Policy
* Finance & transactions associated with founding, building, partnering and exiting
* Law, Intellectual Property, Regulation, Reimbursement
* Bioethics

Recent Special Editions have focused on the topics of: Commercialization and Innovation, Entrepreneurship Boot Camp 2.0 (sponsored annually by the Biotechnology Innovation Organization), Transformative Technologies in Biopharma, Ecosystems and Clusters, and Recognizing and Celebrating Innovators and Innovation (annually). Special Editions in the planning phase for 2022 include Precision Medicine, and Regenerative Medicine.

**J. Commercial Biotechnology Submission Guidelines**

The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.

**Format of submissions**

Papers should be in the range of 2,500 words to 4,000 words (but shorter and longer papers will be considered). Submissions should be single-spaced, and supplied electronically, preferably in Word (.docx) format.

All contributing authors should be listed in the order preferred by the authors; along with their affiliations.

**Abstract**

All papers should be accompanied by a brief abstract of up to 200 words setting out the aims and scope of the paper and summarizing the skills/knowledge the reader will take away from it.

**References**

The citations should follow the Vancouver system, marked by a superscript number, closed up to the preceding text, but outside any punctuation that is part of the surrounding sentence. Pairs of citations should be separated with an unspaced comma1,2

Personal communications should be listed as such where they are cited in the text, and not listed in the references.

References are placed in a consecutive numerical list at the end of the paper. The sequence follows the order of first-citation in the text. References cited only in tables or captions are placed in the sequence according to the first reference in the text to that table or figure. When a work is cited more than once, the number of the original reference should be repeated (not new numbers generating extra items in the reference list cross-referring back to the original).

## Photographs, figures and graphics

Photographs and illustrations supporting papers should be submitted where appropriate.

The journal is printed in full color, so you may supply your figures with color.

## Tables and graphs

Tables and graphs should be submitted in their original Word/Excel format. PowerPoint slides and screen grabs can be used, provided that there is sufficient resolution for printing.

## Peer Review procedure

All papers submitted for this publication will be subject to review by the organizing/Guest Editors of this Special Edition, who may also solicit reviews by the Session Moderators. As needed, we may also engage the Editorial Board, and Editorial Advisory Board members of J. Commercial Biotechnology.

## Copyright

Authors are responsible for obtaining permission from copyright holders for reproducing through any medium of communication those illustrations, tables, figures or lengthy quotations previously published elsewhere. Add your acknowledgements to the typescript, preferably in the form of an "Acknowledgements" section at the end of the paper. Credit the source and copyright of photographs or figures in the accompanying captions.

The journal's policy is to own copyright in all contributions. Before publication, authors assign copyright to the Publishers, but retain their rights to republish this material in other works written or edited by themselves, subject to full acknowledgement of the original source of publication.

The journal mandates the Copyright Clearance Center in the USA and the Copyright Licensing Agency in the UK to offer centralized licensing arrangements for photocopying in their respective territories.

No contribution will be accepted which has been published elsewhere, unless it is expressly invited or agreed by the Publisher and Editor in Chief of JCB. Papers and contributions published become the copyright of the Publisher, unless otherwise agreed.